"You will have to get used to it my friend, there is no other way around. Since I am not quite sure if what I am about to write is gonna be again some kinda of breaking the rules and regulations of this forum but ...let’s try to explain something: no matter what your thinking is and what your imagination is telling you, this is not a value investing, it’s highly speculative and high risk and the prices of the shares reflect exactly the situation."

That's not rule breaking. Yes, biotech investing is risky. Especially so for a small biotech company like Resverlogix with one single molecule in clinical trials. However, your post fails to acknowledge: 1) how late stage apabetalone is; and 2) how emotional/fickle the market can be.

Apabetalone is nearly 3 years into their Phase 3 cardiovascular outcomes trial and is expected to complete patient dosing by year end and report top-line data in Q1 2019. It is a first-in-class molecule (bromodomain-2 selective BET inhibitor) with no competitors on the horizon. All other BET inhibitors are only in oncology and due to their poor safety profile are not amenable to chronic use. Apabetalone has passed 7 DSMB checks, has already proceeded through various Phase 1 and 2 trials, and really the only notable safety concern is mild, transient elevations in liver transaminases in a small number of patients.

As we all know, the market is very emotional and fickle. As the bookends continue to narrow for the end of dosing and top-line read out, and especially if more analyst and press coverage starts up, Resverlogix will be in the spotlight. I'm not claiming that this investment is completely de-risked. However, crazy things can happen with the share price with rumors and expectations as the bookends close. A Phase 3 drug nearing the end of a cardiovascular outcomes trial for patients with unmet need may be the perfect recipe for a wild ride in the coming months; especially if it is  fueled by rumor, expectations and hopefully more analyst/press coverage. 

BearDownAZ